

# Hendrik Rathke

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4860585/publications.pdf>

Version: 2024-02-01

30  
papers

2,762  
citations

331538

21  
h-index

454834

30  
g-index

31  
all docs

31  
docs citations

31  
times ranked

2156  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | <sup>68</sup> Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 801-805.   | 2.8 | 874       |
| 2  | Targeted $\alpha$ -Therapy of Metastatic Castration-Resistant Prostate Cancer with <sup>225</sup> Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1624-1631.  | 2.8 | 367       |
| 3  | Targeted $\alpha$ -Therapy of Metastatic Castration-Resistant Prostate Cancer with <sup>225</sup> Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control. <i>Journal of Nuclear Medicine</i> , 2018, 59, 795-802.  | 2.8 | 322       |
| 4  | Nomograms to predict outcomes after <sup>177</sup> Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. <i>Lancet Oncology</i> , The, 2021, 22, 1115-1125.   | 5.1 | 120       |
| 5  | Impact of <sup>68</sup> Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas. <i>Journal of Nuclear Medicine</i> , 2021, 62, 779-786.   | 2.8 | 113       |
| 6  | Targeted alpha therapy of mCRPC: Dosimetry estimate of <sup>213</sup> Bismuth-PSMA-617. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 31-37.   | 3.3 | 107       |
| 7  | The Role of <sup>68</sup> Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1331-1336.  | 2.8 | 106       |
| 8  | Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing <sup>225</sup> Ac-PSMA-617 RLT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 139-147.   | 3.3 | 72        |
| 9  | Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [ <sup>177</sup> Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 113-122. | 3.3 | 72        |
| 10 | Repeated <sup>177</sup> Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq. <i>Journal of Nuclear Medicine</i> , 2018, 59, 459-465.   | 2.8 | 68        |
| 11 | Patients Resistant Against PSMA-Targeting $\alpha$ -Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes. <i>Journal of Nuclear Medicine</i> , 2020, 61, 683-688.  | 2.8 | 61        |
| 12 | [ <sup>153</sup> Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3011-3013.  | 3.3 | 60        |
| 13 | FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1754-1755.   | 3.3 | 58        |
| 14 | <sup>68</sup> Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas – Imaging analysis and histological validation. <i>Radiotherapy and Oncology</i> , 2021, 160, 192-201.   | 0.3 | 40        |
| 15 | Response Prediction of <sup>177</sup> Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase. <i>Journal of Nuclear Medicine</i> , 2020, 61, 689-695.  | 2.8 | 39        |
| 16 | Efficacy and Safety of <sup>177</sup> Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. <i>European Urology</i> , 2020, 78, 148-154.   | 0.9 | 39        |
| 17 | Dosing <sup>225</sup> Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 54-63.  | 3.3 | 35        |
| 18 | Intraindividual Comparison of <sup>99m</sup> Tc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand <sup>99m</sup> Tc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1373-1379.                                      | 2.8 | 31        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Two Tumors, One Target. <i>Clinical Nuclear Medicine</i> , 2021, 46, 842-844.  | 0.7 | 30        |
| 20 | FAP-specific PET signaling shows a moderately positive correlation with relative CBV and no correlation with ADC in 13 IDH wildtype glioblastomas. <i>European Journal of Radiology</i> , 2020, 127, 109021.   | 1.2 | 28        |
| 21 | Dosimetry Estimate and Initial Clinical Experience with <sup>90</sup> Y-PSMA-617. <i>Journal of Nuclear Medicine</i> , 2019, 60, 806-811.  | 2.8 | 27        |
| 22 | The role of combined ion-beam radiotherapy (CIBRT) with protons and carbon ions in a multimodal treatment strategy of inoperable osteosarcoma. <i>Radiotherapy and Oncology</i> , 2021, 159, 8-16.   | 0.3 | 21        |
| 23 | The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4067-4076. | 3.3 | 20        |
| 24 | First patient exceeding 5-year complete remission after 225Ac-PSMA-TAT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 311-312.   | 3.3 | 18        |
| 25 | Validating the Xerostomia Inventory in a radiation-induced xerostomia population in German language. <i>Oral Diseases</i> , 2019, 25, 1744-1750.   | 1.5 | 13        |
| 26 | Integration of CT urography improves diagnostic confidence of 68Ga-PSMA-11 PET/CT in prostate cancer patients. <i>Cancer Imaging</i> , 2017, 17, 30.   | 1.2 | 8         |
| 27 | Impact of sialendoscopy on improving health related quality of life in patients suffering from radioiodineinduced xerostomia. <i>Nuklearmedizin - NuclearMedicine</i> , 2018, 57, 160-167.   | 0.3 | 6         |
| 28 | [18F]PSMA-1007 PET Improves the Diagnosis of Local Recurrence and Lymph Node Metastases in a Prostate Cancer Patient With a History of Bilateral Hip Arthroplasty. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 111-113.                           | 0.9 | 4         |
| 29 | Prognostic markers for overall survival and outcome to LuPSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5548-5548.                                     | 0.8 | 1         |
| 30 | Efficacy and safety of 177Lu-PSMA radionuclide treatment in patients with diffuse bone marrow involvement: A multicenter retrospective study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17543-e17543.  | 0.8 | 1         |